The LEAD Coalition has submitted a letter providing input on House Energy and Commerce Committee Chair Cathy McMorris Rodgers’ “Reforming the National Institutes of Health Framework for Discussion.” The LEAD Coalition letter encourages a congressional process that ensures Alzheimer’s disease and related disorders research continues to be addressed collaboratively across NIH with a life-course, person-centered […]
LEAD Coalition July 29th, 2024 News
Read the July 29th LEAD Coalition Newsletter below.
LEAD Coalition June 27th, 2024 News
Read the June 27th LEAD Coalition Newsletter below.
LEAD Coalition submits public comments for FDA review of donanemab
Today, 265 LEAD Coalition member organizations and allies sent a joint public comment letter to the U.S. Food and Drug Administration (FDA) regarding its review of the supplemental biologics license application for donanemab (BLA 761248) for the treatment of mild cognitive impairment and early dementia due to Alzheimer’s disease. The letter expresses full confidence in […]
LEAD Coalition May 29th, 2024 News
Read the May 29th LEAD Coalition Newsletter below.
LEAD Coalition renews call for Congress to boost FY 2025 dementia funding
Today, 383 LEAD Coalition member organizations and allies sent a joint letter urging Congress to continue to prioritize investments to address Alzheimer’s disease and related disorders (AD/ADRD) through dementia-focused FY 2025 appropriations. The letter calls for the FY 2025 appropriations bills to include substantial increases in funding to strengthen the national response to AD/ADRD and […]
LEAD Coalition April 29th, 2024 News
Read the April 29th LEAD Coalition Newsletter below.
LEAD Coalition March 27th, 2024 News
Read the March 27th LEAD Coalition Newsletter below.
LEAD Coalition February 28th, 2024 News
Read the February 28th LEAD Coalition Newsletter below.
LEAD Coalition January 31st, 2024 News
Read the January 31st LEAD Coalition Newsletter below.